Welcome to the e-CCO Library!

P721 Early vedolizumab trough levels are associated with induction therapy outcome
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. O’Connell1, R. Corcoran1, R. Argue1, P. McDonagh1, M.S. Ismail2, G. Cullen3, G. Doherty3, K. Hartery1, M. Healy4, M. McCormack4, F. MacCarthy1, S. McKiernan1, A. O’Connor2, B. Ryan2, D. McNamara2, D. Kevans1

Created: Thursday, 30 January 2020, 10:12 AM
P721: A switch in the prevalence ratio of Crohn's disease vs. ulcerative colitis in Israel between 2003 and 2015 – a report from the epi-IIRN group
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Friedman M.*1, Odes S.2, Balicer R.3, Hoshen M.3, Cohen D.3, Rosenblum J.4, Zigman N.4, Goren I.4, Lederman N.5, Matz E.6, Dushnitzky D.6, Borovsky N.6, Gavish M.7, Focht G.1, Avitzour M.1, Axelrod R.1,7, Chowers Y.8, Eliakim R.9, Ben-Horin S.9, Dotan I.10, Israeli E.11, Levy Z.12, Benchimol E.13, Turner D.1

Created: Wednesday, 20 February 2019, 10:36 AM
P721: Effect of thalidomide on clinical remission in adult with refractory crohn disease, a multicentre, randomised, double-blind clinical trial
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

X. Peng*1, M. Zhi1, Q. Cao2, P. Hu1, X. Gao1

Created: Friday, 22 February 2019, 9:41 AM
P721: Faecal microbiota analysis with body composition and nutritional habits simultaneously amongst Crohn’s disease patients
Year: 2022
Source: ECCO'22
Authors: Bálint, A.(1);Bacsur, P.(1);Resál, T.(1);Jójárt, B.(2);Gyuris, Z.(3);Jaksa, G.(3);Pintér, L.(3);Takács, B.(4);Pál, S.(5);Gácser, A.(5);Szántó, K.J.(1);Rutka, M.(1);Bor, R.(1);Fábián, A.(1);Farkas, K.(1);Maléth, J.(2);Szepes, Z.(1);Molnár, T.(1);
Created: Friday, 11 February 2022, 3:56 PM
P721: Psychological care is needed and welcomed by patients with inflammatory bowel disease under routine care
Year: 2018
Source: ECCO '18 Vienna
Authors:

T. Lores1*, C. Goess1, C. Hrycek2, R. Grafton1, J. Hughes1, L. Cronin1, A.L. Burke3, K.L. Collins3, A. Chur-Hansen4, A. Mikocka-Walus5, J.M. Andrews1

Created: Thursday, 21 February 2019, 9:14 AM
P721: Treatment of Ulcerative Colitis with OSE-127 (lusvertikimab), a Strict IL-7Rα Antagonist, Non-Cytotoxic Monoclonal Antibody
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Corallo, F.(1)*;
Created: Friday, 14 July 2023, 11:12 AM
P722 Upadacitinib was not associated with anaemia in patients with moderately to severely active ulcerative colitis: Results from the U-ACHIEVE study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G. D’Haens1, X. Hebuterne2, P.D.R. Higgins3, E.V. Loftus- Jr.4, W. Zhou5, A.P. Lacerda5, W. Xie6, J. Liu6, S. Danese7

Created: Thursday, 30 January 2020, 10:12 AM
P722: Compositional differences of gut microbiome using taxonomic profiling in patients with ulcerative colitis after treatment with vedolizumab
Year: 2022
Source: ECCO'22
Authors: Yoon, A.(1,2,3);Kim, K.(1);Oh, K.(1);Kim, E.S.(4);Kim, E.H.(4);Kim, S.(5);Jeong, J.Y.(4);Kweon, M.N.(5);Hwang, S.W.(1,3);Park, S.H.(1,3);Myung, S.J.(1);Yang, S.K.(1,3);Ye, B.D.(1,3);
Created: Friday, 11 February 2022, 3:56 PM
P722: Prediagnostic serum vitamin D levels and risk of inflammatory bowel disease: a pan-European, nested case-control study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Opstelten J.*1, Chan S.2,3, Hart A.2,3, van Schaik F.1, Siersema P.4, Lentjes E.5, Khaw K.-T.6, Luben R.6, Key T.7, Boeing H.8, Bergmann M.8, Overvad K.9, Palli D.10, Masala G.10, Racine A.11,12, Carbonnel F.11,12, Boutron-Ruault M.-C.11, Tjønneland A.13, Olsen A.13, Andersen V.14, Kaaks R.15, Kühn T.15, Tumino R.16, Trichopoulou A.17, Verschuren M.18,19, Witteman B.20,21, Oldenburg B.1

Created: Wednesday, 20 February 2019, 10:36 AM
P722: Results of the STAR study: management of ulcerative colitis in private practice in france, in the first years following diagnosis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Bourreille*1, S. Nancey2, A. Attar3, H. Sokol4, L. Peyrin-Biroulet5, Y. Bouhnik6, X. Roblin7, G. Bonnaud8

Created: Friday, 22 February 2019, 9:41 AM
P722: Symptom-based disease trajectories Identify a population of early super-responders in ulcerative colitis achieving complete disease control under targeted therapy
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Tran, F.(1,2)*;Brard, R.(3);Flechsenhar, K.(4);Aden, K.(1,2);Rosenstiel, P.(2);Agueusop, I.(3);Schreiber, S.(1,2);
Created: Friday, 14 July 2023, 11:12 AM
P722: Trough levels, drug switching and antidrug antibody loss: Analysis of real-life infliximab and adalimumab data in IBD
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Ho1, T. Sipponen1,2*, T.S. Jokiranta1,3

Created: Thursday, 21 February 2019, 9:14 AM
P723 Therapeutic thresholds for golimumab serum concentrations during induction and maintenance: Results from the GO-LEVEL study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Samaan1, G. Cunningham1, G. Tamilarasan1, K. Rawstron2, K. Hawash2, L. Beltran2, S. Ray1, J. Mawdsley1, S. Anderson1, J. Sanderson1, Z. Arkir2, P. Irving1

Created: Thursday, 30 January 2020, 10:12 AM
P723: Comparison of the Persistence Rates of Biologic Agents in Paediatric Crohn's Disease Patients (Japanese Paediatric IBD Registry Study)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Nishida, D.(1);Ishige, T.(2);Arai, K.(3);Shimizu, H.(3);Iwama, I.(4);Nambu, R.(4);Kunisaki, R.(1);Yaguchi, K.(1)*;Mizuochi, T.(5);Murakoshi, T.(6);Saito, T.(7);Kato, S.(8);Kudo, T.(9);Iwata, N.(10);Inoue, M.(11);Yodoshi, T.(12);Hagiwara, S.I.(13);Toita, N.(14);Tajiri, H.(15);Mochizuki, T.(16);Kakuta, F.(17);Kumagai, H.(18);Noguchi, A.(19);Sasaki, M.(20);Nishimata, S.(21);Aomatsu, T.(22);Hirano, Y.(3);Shimizu, T.(23);
Created: Friday, 14 July 2023, 11:12 AM
P723: Effectiveness and persistence of vedolizumab in patients with Inflammatory bowel Disease: Results from the Belgian REal-LIfe study with VEdolizumab (Be-RELIVE)
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Reenaers1*, A. Cremer2, O. Dewit3, B. de Vroey4, W. Van Moerkercke5, P. Bossuyt6, V. Muls7, J. Imschoot8, S. Block8, A. Hantson8, P. Van Hootegem9

Created: Thursday, 21 February 2019, 9:14 AM
P723: Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with iron isomaltoside or ferric carboxymaltose: results of a prospective cluster randomised cohort study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. E. Detlie*1,2, J. C. Lindstrøm3, M. E. Jahnsen1, E. Finnes4, H. Zoller5, B. Moum4,6, J. Jahnsen1,2

Created: Friday, 22 February 2019, 9:41 AM
P723: SexIDI study – sexual satisfaction in inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Roseira J.*1, Tavares de Sousa H.1, Marreiros A.2, Estevens D.3, Queiros P.1, Vaz A.M.1, Gago T.1, Contente L.1, Guerreiro H.1

Created: Wednesday, 20 February 2019, 10:36 AM
P724 Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Ungar1,2, Z. Ben-Shatach1,2, T. Ziv-Baran2,3, E. Fudim1,2, M. Yavzori1,2, O. Picard1,2, L. Selinger1,2, B. Weiss2,4, U. Kopylov1,2, R. Eliakim1,2, S. Ben-Horin1,2

Created: Thursday, 30 January 2020, 10:12 AM
P724: Appendectomy is not a treatment option for ulcerative colitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Myrelid P.1,2, Landerholm K.*3,4, Nordenvall C.5,6, Pinkney T.D.7, Andersson R.E.2,3

Created: Wednesday, 20 February 2019, 10:36 AM
P724: Unchanged infliximab serum concentrations after switching from the originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease: Results from a prospective study (SECURE)
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Strik1*, W. van de Vrie2, J. Bloemsaat-Minekus3, M. Nurmohamed4, P. Bossuyt5, A. Bodelier6, T. Rispens7, Y. van Megen3, G. D'Haens1

Created: Thursday, 21 February 2019, 9:14 AM